Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy
Sponsor

Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy

Poland Alpejska 42, 04-628 Warsaw, Poland

About the sponsor

Research activity includes anticoagulation management around transseptal structural procedures, with attention to Transcatheter Edge-to-Edge Repair and Left Atrial Appendage Closure. The focus is on balancing thromboembolic protection and bleeding risk in patients undergoing invasive cardiac intervention.

  • Transseptal cardiac procedures
  • Anticoagulant therapy
  • Stroke prevention
  • Bleeding risk management

Additional interest extends to antiplatelet strategies after left atrial appendage closure in patients with complex cardiovascular comorbidity.

About Specializations

Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy runs clinical trials in conditions such as Atrial fibrillation, Hypertension, Univentricular heart, Fontan procedure, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

9 clinical trials

Hypertension

Recruiting

Study of Optimal Treatment for Uncontrolled Hypertension Using Triple Drug Combinations (Olmesartan/Amlodipine/Hydrochlorothiazide or Perindopril/Indapamide/Amlodipine) with Additional Diuretics

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Amlodipine
  • Sponsor:Agencja Badań Medycznych

Univentricular heart+1

Recruiting

Study on Sildenafil for Adults with Single Ventricle Heart Condition Post-Fontan Surgery

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Sildenafil
  • Sponsor:Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy

Cardiomyopathy

Recruiting

Study on Valsartan and Sacubitril for Preventing Disease Progression in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Sacubitril
  • Sponsor:Agencja Badań Medycznych

Coronary artery disease+2

Recruiting

Study on the Effects of Semaglutide, Dapagliflozin, and Metformin in Patients with Coronary Artery Disease and Prediabetes

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy

Atrial fibrillation

Not yet recruiting

Study of acetylsalicylic acid and clopidogrel treatment duration after left atrial appendage closure in patients with atrial fibrillation

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy

Atrial fibrillation

Not yet recruiting

Study of acetylsalicylic acid and clopidogrel treatment after left atrial appendage closure in patients with atrial fibrillation and chronic kidney disease

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy

Atrial fibrillation+1

Not yet recruiting

Title: Evaluation of optimal timing for heparin anticoagulation in patients undergoing transseptal heart procedures (TEER or left atrial appendage closure)

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Heparin Sodium
  • Sponsor:Agencja Badań Medycznych

Atrial fibrillation

Not recruiting

Study on Early Ablation and Use of Amiodarone, Beta-Blockers, or Sotalol for Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Bisoprolol Fumarate
  • Sponsor:Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy

Hypertrophic cardiomyopathy

Not recruiting

Study of empagliflozin to improve exercise capacity in patients with hypertrophic cardiomyopathy

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin
  • Sponsor:Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.